BioSyent secures a spot among Canada’s fastest-growing companies in 2026, as recognized by *The Globe and Mail*. The biotech firm specializes in synthetic biology solutions for industrial and healthcare applications. The company’s inclusion highlights its rapid expansion and innovation in the sector.
BioSyent Inc. declares a quarterly dividend of **$0.055 per common share** for Q3 2026, matching its Q2 2026 payout. The dividend, payable in Canadian Dollars, qualifies as an 'eligible dividend' under tax regulations. Shareholders of record as of August 31, 2026, will receive the payment on September 15, 2026.
BioSyent Inc. reports its financial performance for the second quarter and first half of 2026. The company provides an update on revenue, expenses, and operational metrics without disclosing specific figures in the headline release.
BioSyent Inc. reports its financial performance for Q4 and FY 2025, ending December 31, 2025. The company, listed on the TSX Venture Exchange under the ticker RX, provides key financial highlights for investors and stakeholders. The results outline operational metrics and fiscal outcomes for the closing year.
Mar 2026BioSpaceNews article
BioSyent
BioSyent licenses and markets approved specialty pharmaceutical products for Canadian patients through community, specialty, and international business units.
